Regulatory Landscape for Industrials M&A: HSR, CFIUS, and EPA

Introduction

Every industrials M&A transaction of meaningful size encounters at least one regulatory framework that affects timing, certainty, and deal structure. The three most common are HSR (Hart-Scott-Rodino antitrust filing), CFIUS (Committee on Foreign Investment, for transactions involving foreign acquirers and national security), and EPA environmental review (for transactions involving manufacturing sites with environmental contamination). A straightforward domestic industrial acquisition might require only an HSR filing (adding 30-45 days). A cross-border defense acquisition might require HSR plus CFIUS plus ITAR compliance review (adding 6-12+ months). A manufacturing company with contaminated sites might require EPA environmental assessment that affects both the deal timeline and the purchase price (through environmental indemnity provisions and remediation cost estimates).

For industrials bankers, regulatory awareness at the deal screening stage prevents timeline surprises, allows proper structuring of regulatory risk allocation (who bears the cost of delay or denial), and demonstrates execution credibility with clients and counterparties.

The Hart-Scott-Rodino Act requires pre-merger notification to the FTC and DOJ for transactions exceeding specified size thresholds. The baseline size-of-transaction threshold increases to $133.9 million in 2026 (up from $126.4 million in 2025, approximately 6% increase). In fiscal year 2024, companies notified the agencies of 2,031 transactions, approximately one-quarter valued above $1 billion.

HSR Filing and Waiting Period

The Hart-Scott-Rodino Act requires parties to a qualifying transaction (above the size threshold, with certain exemptions) to file notification forms with the FTC and DOJ and observe a waiting period (typically 30 days for a standard filing) before closing. During the waiting period, the agencies review the filing to determine whether the transaction may substantially lessen competition. If the agencies have concerns, they can issue a "Second Request" for additional information, which extends the process by 3-6 months and significantly increases the compliance cost (Second Requests can involve millions of documents). If no Second Request is issued, the parties can close after the waiting period expires.

The February 2025 HSR rule changes represent the most sweeping updates to the notification form in 48 years. The new requirements include disclosure of additional internal documents related to deal rationale, synergies, and competition; information about each party's prior acquisition history (directly relevant for PE roll-up strategies where the FTC is scrutinizing serial acquisitions); and expanded narrative descriptions of competitive dynamics. These enhanced disclosure requirements increase the preparation time and cost for HSR filings, particularly for PE-backed platforms that must document their cumulative acquisition history.

CFIUS review applies to transactions where a foreign person or entity acquires control of, or certain rights in, a US business. For industrials, CFIUS is most relevant for A&D transactions (defense contractors, suppliers with classified programs, companies producing ITAR-controlled products) and for transactions involving critical technologies (semiconductors, advanced materials, AI, quantum computing).

The 2025 "America First Investment Policy" created a tiered CFIUS framework: investors from "Excepted Foreign States" (Australia, Canada, New Zealand, UK) face streamlined review, allied nations face standard 45-90+ day review, and investors from "countries of concern" (China, Russia) face heightened scrutiny or effective blocking. The CFIUS process adds 45-90+ days to deal timelines and can result in transaction blocking, mandatory conditions (proxy board arrangements, operational restrictions), or deal abandonment.

For industrials bankers, the CFIUS assessment should occur at the deal screening stage, not after the LOI is signed. Identifying CFIUS-sensitive elements (classified programs, ITAR products, critical technologies, proximity to military installations) early allows the banker to either exclude foreign buyers from the process or structure the transaction with CFIUS-specific provisions (reverse termination fees for CFIUS denial, "hell-or-high-water" covenants requiring the buyer to accept reasonable mitigation conditions).

Industrial manufacturing transactions frequently involve environmental risk that does not exist in service, technology, or financial services M&A. Manufacturing sites may have soil or groundwater contamination from decades of chemical use, storage tank leaks, or waste disposal. The EPA's Superfund program (CERCLA) can impose liability on current and former property owners for cleanup costs at contaminated sites, and this liability can be joint and several (meaning a single owner can be held responsible for the full cleanup cost regardless of their contribution to the contamination).

Environmental due diligence in industrial M&A typically includes Phase I and Phase II Environmental Site Assessments (ESAs), review of regulatory compliance history (EPA enforcement actions, state environmental violations), assessment of pending or potential remediation obligations, and quantification of environmental liability (remediation cost estimates that are deducted from the enterprise value or covered by seller indemnities).

The EPA regulatory environment is evolving rapidly. New PFAS drinking water standards, updated air emission regulations, greenhouse gas reporting requirements, and evolving waste disposal classifications all create regulatory risk that affects industrial company valuations and deal structures. A manufacturing company that is currently compliant but faces upcoming regulatory requirements (e.g., new emission controls that will cost $10-20 million to implement) has an implicit environmental liability that sophisticated buyers will factor into their valuation.

For industrials bankers, the regulatory timeline directly affects the deal schedule and the purchase agreement provisions. The ticking fee (compensating the seller for the cost of extended closing timelines caused by regulatory review), the reverse termination fee (protecting the seller if the buyer cannot obtain regulatory approval), and the regulatory effort covenant (specifying what steps the buyer must take to obtain approval) are all negotiated provisions that allocate regulatory risk between buyer and seller.